July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Clinical Severity Grading Tool for Cicatrising Conjunctivitis: A Validation Study
Author Affiliations & Notes
  • Hon Shing Ong
    Corneal and External Diseases / Tissue Engineering and Stem Cell, Singapore National Eye Centre / Singapore Eye Research Institute, Singapore, Singapore
    Corneal and External Diseases, Moorfields Eye Hospital / UCL Institute of Ophthalmology, London, United Kingdom
  • Darwin Minassian
    Epidemiology, EpiVision Ophthalmic Epidemiology Consultants, London, United Kingdom
  • Saaeha Rauz
    Ophthalmology, University of Birmingham, Birmingham, United Kingdom
  • Jodhbir S Mehta
    Corneal and External Diseases / Tissue Engineering and Stem Cell, Singapore National Eye Centre / Singapore Eye Research Institute, Singapore, Singapore
  • John K Dart
    Corneal and External Diseases, Moorfields Eye Hospital / UCL Institute of Ophthalmology, London, United Kingdom
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 1165. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Hon Shing Ong, Darwin Minassian, Saaeha Rauz, Jodhbir S Mehta, John K Dart; Clinical Severity Grading Tool for Cicatrising Conjunctivitis: A Validation Study. Invest. Ophthalmol. Vis. Sci. 2018;59(9):1165.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Cicatrising conjunctivitis (CC) refers to a group of sight-threatening conditions associated with conjunctival scarring and inflammation. No validated clinical system exists for measuring the severity and activity of CC.

We have designed a tool based on previously described activity, damage indices of ocular surface disease, and findings of a cross-sectional study in mucous membrane pemphigoid (MMP).1 The tool uses objective parameters to measure disease activity and severity, such as an inflammation grading scale using photographs and scarring assessment using fornix depth measurements (FDM). We aim to validate this system as a standardised assessment tool in CC.

Methods : Design: Cross-sectional cohort study

Participants: 74 patients (147 eyes) with CC

To test for inter-observer variability, all patients underwent clinical assessment by 2 independent examiners using the grading tool at a single visit. To test for intra-observer variability, all patients returned within 2 weeks and clinical assessment using the same tool was repeated by the same 2 examiners. In a subset of Stevens Johnson Syndrome (SJS) patients, we also compared our grading tool to a published but non-validated grading system for ocular SJS (Sotozono, et al 2007).

Results : 55 patients (109 eyes) had ocular MMP and 19 patients (38 eyes) had ocular SJS [mean age: 64.0±15.5 years; 42/74(56.8%) female]. Grading parameters with good inter- and intra-observer agreement include: ocular inflammation, limitation in motility, symblepharon measurement, FDM, subconjunctival fibrosis, corneal vascularization, corneal opacity, conjunctival and corneal keratinization [Intra-class correlation coefficient (ICC) 1.00, p<0.001]. Overall, this assessment tool delivered good inter-observer [ICC 0.91, p<0.001] and intra-observer agreement [ICC observer 1: 0.91, p<0.001; ICC observer 2: 0.98, p<0.001]. In SJS cases, there was good agreement between our tool and the Sotozono system [ICC 0.83, p<0.001]; this was also observed when the Bland-Altman plot was applied.

Conclusions : This study validates our severity grading tool, demonstrating that it is a reliable method for assessing patients with CC. This tool can be used for clinical documentation and in future studies evaluating CC therapies.

1 Ong HS, et al. Mucous membrane pemphigoid with ocular involvement: the clinical phenotype and its relationship to direct immunofluorescence findings. Ophthalmology In press(2017).

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×